                           ˿µϣ20101001գ

10.10.01, ɽ˵ҽѧ̫ԡ
10.10.01, ӢȻйԱ⵽Ϯ
10.10.01, Ϸĩ˭ɾФ
10.10.01, ʸФеƭ¹ҽ
10.10.01, ѧļͦФ
10.10.01, ձѧලΪ˶Թ
10.10.01, ¡Фױ Ӧ衰ʺǡ
10.10.01, ӽڹ˿Ժʿ
10.10.01, ơФİ֮͢м
10.10.01, zhaowsФʵûа취
10.10.01, CarnegieФġԴҽԺĹִգ˵ʲô
10.10.01, ɽԺʿҽĿ
10.10.01, ҽֳ⡶ʷġ
10.10.01, divingbirdΪιӡ
10.10.01, oztigerƭڹĴĦֿ캣пʵ
10.10.01, 335PH4CVרļժ룩
10.10.01, ·͸磺ĶзĻָЧ
10.10.01, ҽſҩ һ˴25Ԫ

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

Ӱɽ˵˵ҽѧֻҩ֤
̫ܽˡΪҽƺ͡δǿѧġ
ҽơ͡δ֮Ҳǿѧ롣ִ
ѧҲƺԤΪҽڿѧûҪҽ˵

ɽ˵ʱűʱһѣˮ
֭磬书ЧҲѱ֤ɽҽ
ܲϤǸǽ顶󷽡ģʱ䳭һ¶ѡʱ
ͬʱ¼űЧķӣǲҩ

    磬ǡҽҩĽʵҽû̫Ĺ
ϵǴӻƻȡűĻѧҩҩΪҩ
أʹоҲƻ˻ԣűЧ

ɽ˵ҽѧ̫

20101001չձ

ɽϯҽҽԺ² ̸ҽ:
μԲزҽسϸȾȣҩȿ졣
֮ҽҩ߹ܽе𵽺ãһЩԲķҲ
ˡ
ɽ

Ѷ  ͨѶԱŷ룩˵ҽѧֻҩ
֤̫ܽˡΪҽƺ͡δǿѧ
ġ죬ɽԺʿΪҽѧԺҽԺճľʹרƲ
ʱܼרãԼҽġҽδЦڶ
ҽǡҽΡѲΪҽҩҪչҲѭ֤ҽѧķ
Чо

ҽδڶҽǡҽΡѲ

ҽҽδ֮ҽҽ֮ҽҽѲ֮ɽ
ѿڽƴҽ˼βЦڶҽǡҽ
ѲָĿǰҹϰҪֱַѪ
Ρ򲡵ȣЩ10~20Ǳڣҽδ
ͨıʽԤɽʡ

ҽ֮ǻϵģǿӦ˵һƣ
ҿصһɽоҽ˵ǰ
ҽǼ򵥵ذɱˣûˣҲˣҽֱӰ
𣬶а桱Ʋ˵ӳ
ƣҲⷽת䣬ҽйصġ
ڱ˵һҽ˸ǳԵӣһ
εĲأҲӰ죬ˣͨˣ
Ҳõ⡣

ʱűʱһѣˮ֭
磬书ЧҲѱ֤

ҲϲҽϣΪѽϣҽɲչ

ɽΪҩǧľ˲ٺöж;
ѭ֤ҽѧż˵ҽѧֻҩ֤
̫ܽˡΪҽƺ͡δǿѧġ

ҲϲҽϣΪѽϣҽɲչ
ɽ˵μԲزҽسϸȾȣҩȿ졣
֮ҽҩ߹ܽе𵽺ãһЩԲķ
ҲˡҽܳڴڣȻĵ

ȻɽΪ⼸ʮҽķչ·ûϸѭ֤
ҽѧķЧоָҽִ·ͻƵ㣬һ
ҩһҽǣǰΪѾΪȫ繫ϵű
ҩ߿ɽִX⡢CTȼֶΣҽӹǡǵ޴
ƾ顣

ҽԱȣ

ҽ ǰǼ򵥵ذɱˣûˣҲˡ

ҽ ֱӰ𣬶а桱Ʋ
˵ӳҲⷽת䡣

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

йԱ⵽Ϯ

ߣDavid Cyranoski
ӢȻ2010929

룺ӣ

йѧܱһҰϷ829գڴӱһ
ؼҵ·ϣ⵽ϮλڹȥʮվϽ¶ѧߵǰ
ﻯѧѧ߱׷ϣ

ǼƻҪɱң˵ұΨһ취ɱҡ
ˣС˺Ѫ6£һйѧļ߷
øֽϮƸء

921գ人ͬҽѧԺҽФ߻
ϮФ޷ϵϷۣ򱱾永
˵ФʮļԹɱߵĻڻ

ФͷӴδ̸ǵ·ڻԼ
ڷͥϷ档Ф뷽ԼĳͻФһ
𣬸ּüѻ׵˵Ĳ˻ָС㹦ܡ漰
ؽ񾭻·ФзͬСɵ87ɹʡ2005꣬ѡ
йѧȨйѧԺԺʿ

ФǿʼڷӵվФ˵
20059£ڡƼϷһƪ£Ф
˵ŦԼѧĸڣֻڡĻ˵Фе26ƪ
Ӣֻ4ƪģѧժҪ

֪ӵǷӰйѧԺľФûеԺʿ
ԺФ5߷˺ӵվָΪͶ
ṩƽ̨عǵĵˣеһϣӮ
δСͬʱԡФڳȥ꣬һϵ
Чԣܵ˶Ϯ

ʦ˵ɷ2030ФĲˣ
֢⡣죬ѧ־˸Ʒ״ٴ
Ĳȷͬʱ۳ӦΪֻʵԵ

ͬʱûбϮŵֹң˵ҽ
¡

http://www.nature.com/news/2010/100929/full/467511a.html

Published online 29 September 2010 | Nature 467, 511 (2010) | 
doi:10.1038/467511a
News
Brawl in Beijing
Critics of Chinese researchers targeted in physical attacks.

David Cyranoski


Former biochemist Fang Shimin has made enemies after scrutinizing 
scientists reputations.FANG SHIMIN
Science can be a rough game in China. On 29 August, on his way home 
from a tea house in Beijing, Fang Shimin was assaulted. The former 
biochemist  who for the past decade has run a website exposing 
scientific fraudsters  was chased by two men, caught and attacked 
with a hammer.

"I believe they planned to kill me," he says. "The only way to shut me 
up is to kill me." He escaped with only minor cuts and bruises. In June, 
Fang Xuanchang, a journalist who had reported on corruption in science 
in China, was left with more serious injuries after two men assaulted 
him with steel rods.

On 21 September, police arrested Xiao Chuanguo, a urologist at Tongji 
Medical College in Wuhan, on suspicion of master minding both plots. 
Xiao could not be reached for comment, but has confessed his 
involvement to Beijing's police. Fang Shimin says Xiao could face 3C
10 years in prison  or more if the charges become attempted murder.

Xiao and Fang Shimin have never met or spoken, but their paths have 
crossed on the Internet  and in court. Xiao's clash with him, and 
with Fang Xuanchang, revolves around a surgical procedure devised by 
Xiao that aims to restore bladder and bowel function in patients with 
spina bifida or spinal-cord injuries. Xiao reported an impressive 87% 
success rate for the operation, which involves re-routing nerves1,2. 
In 2005, he was nominated for membership of the Chinese Academy of 
Sciences, the elite body of the Chinese scientific world.

Following his nomination, people started posting questions about 
Xiao's claims on Fang Shimin's website 
(http://fangzhouzi-xys.blogspot.com). Then in September 2005, Fang 
Shimin published an essay in Beijing SciCTech Report, which said that 
Xiao was not an associate professor at New York University as he 
states in his CV, but only an assistant professor. Furthermore, the 
article said that only 4 of the 26 English-language publications Xiao 
listed were journal articles  the rest being abstracts from 
conference proceedings.

It is not known if Fang Shimin's article affected the academy's 
decision, but Xiao was not made a member and has since sued Fang 
Shimin for libel five times. Fang Shimin, whose site has been 
criticized for giving contributors a platform for unjustified attacks 
on their enemies3, lost one case and won two, with the other two 
undecided. Meanwhile, criticism of the 'Xiao procedure' has continued. 
Last year, Fang Xuanchang published a series of articles questioning 
its efficacy, which may have prompted the attacks on him.

Beijing-based lawyer Peng Jian says he has interviewed 20C30 patients 
who have experienced side effects after undergoing the Xiao procedure, 
and who are seeking compensation. This summer, the first US trial of 
the treatment reported ambiguous results in The Journal of Urology4, 
and two journal editorials said it should be considered experimental4.

Fang Shimin, meanwhile, is unfazed by the attack. "It won't stop me," 
he says. "I will continue to do what I am doing." 

References
Xiao, C.-G. Proc. Int. Conf. Urol. Shanghai, 2C4 July (2005).
Xiao, C.-G. Eur. Urol. 49, 22-29 (2006). 
Cyranoski, D. Nature 441, 392-393 (2006).
Peters, K. M. et al. J. Urol. 184, 702-708 (2010).

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

˭ɾФ

Ϸĩ Ⱥ ԱϺ
Ϸĩ2010-09-30

Ժʿ죬ȴ׸صѧ 

ФױӵĽһѧʧʧµ
̰ͨ¼ʡʮķФ֮ʵӳй
ơѧۡ˾ỷ䡣

Ф뷽Ӳʮ꣬Фױһ䡣 IC/ͼ

Ф921ձ IC/ͼ

ФϮӵ IC/ͼ

928գ̾һ֮󣬻пƼѧͬҽѧԺЭҽԺ
Ф򾯷ϣԼϮӡԼֻ뽫
ӡñסߡС֮󡰻˵
ɵģ

˵ȻܳʵϣڷϮ֮Фڲϸߵ
Ʒӱǡٰ⣬νֻ뽫һ١֮˵Ҳ
ָΪʹǰġƾ־༭ֻǽѣ
ֲݡΪʮԪǮʵǸļۣõĸֹܡ
Ǵ಻ܽñס

ץһܹԾͷФԵС˵򷽵ԭ
ڣԼûκ;Ž⣩뷽ĳޣԼ桰Ҳ
ܴ⡱

һɹ⻷ҽԵζһ˿̹ǳޣ
˷˼֮٣ڶԴҵ𰸡ɺϵǣ
ϷĩФġФϷ仡й飬йһ
Сʱķ̸ܷΪФϮӣ˵ġһʱ
嶯֮١

һλרҷФױӵĽһѧ
ʧʧµ̰ͨ¼ʡʮķФ֮ʵ
ӳйơѧ˾ỷ䡣˭ɾ
ФФ⡣

Ф˲ʮ꣬ФץΪ֣Ф֧ߣҲΪ
㵡һ֧ФѾʮֵĲϣȡΪ
ӶФʼĩ֤Ф֮ڷӡȻ
Ф

ΪԷӵĴʹץ֮ФԲ֧ߡ
˲΢ڸУڷУǡΰҽ
֮һФǡʽѧ١ġȺĽ

֣Ф֮ûΪФ˱ץ

1. У۾

гرФ֮һ

199771գŦԼѧҽѧԺڵФع人Э
ҽԺΡ

ФУĻعĶİɫʡ磬˵ʱ
ĳعһѧν̵й˱ûع
üʮԪнȴԸһǧԪĹʣûҪһ
Ǯ˵Լԭһͨڣò䡰ٵһΡ
ǹڰûְѡФ˵Ƿʵڸòڶ
ǰȥѾ޴ӿ֤

Фع֮һٶǽ豸ѧУһ
Ϊʱý屨дФԺʿ걨Сָ
ȷʵ˻һٶԪģ̨ѧǣһ̨ҽԺ
һ̨ˣ޷ʹá

Фѧ磬רҵЭĳԱ
ٸͬд򽻵ָΪ߰Ҳྪ֮ζ
ĿǷֹؿۡʣФ
塣뷽ӽа֮ʱ֧ߵã
ФӦƣ侭ʵҪǹƵĸߡһڷӱ
ƻ֮󣬵֪ФȥʮԪ֤ФԲ顣

гرФ֮һȥ꣬йܿѧ
šýФġФɣɵܷרҴ
ҹФѧרҡҽѧβǽеļλܷ
֮һڽϷĩɷʱβ̾Ϊ˸شۡ
֮Фרҵ־ıίְ⣬һĿҲ
ФФǸĿרҡѧרҡпԺԺʿϹμӹ
ФϷ仡μᣬȥýɷʱܵʱ
ФԴƺһֱڻ95յĿѧϣһ
ĿǣӣϹ̨ʱˡ˻һ˫أ֪߽
ΪӣָԺʿ

Ф人ЭҽԺһٶΪûеط飬
һԺ칫ң߿Цãֻð﷿

һλ֪ʿϷĩ߳ƣع֮ФһȶԵλΪ
㵽ϺһҽԺְҽԺФ̸֮󣬸оˡ̫ӡ
ͷ

2. ƽɽ

ФѧеġˡֻпԺԺʿ÷һ

ּФĻع롰ФϷ仡ٴоء

ʵϣ1995꣬Фعְ֮ǰѾƽɽúḺ̌
ϿʼˡФϷ仡ٴ顣

ҵ֪߳ƣʱФոоĶ飬û
ҽ֤ʱ޷Ͽչо

̱ġԴ԰סҽѧδܽ⣬
ФġФϷ仡ͼһ⡣ֻй
ɽèĶֱӦ˵ٴо

ҲǽڡФҵרָڹٴ
оƶȲȫʹй˳Ϊҩ豸¼
顰ݵءһЩдо׶ε¼йٴշ

һλѧרҶϷĩߴ̾й˵ֵǮ

ƽɽϽе飬ЧΣԳաФ
2003귢ڹרҵ־ϵһƪģ˴βٴĹ15̱
ˣ10ЧǣϷĩߵ绰ѯФṩˣһ
ЧֺȴӰ죬һ˵롱˵ͬ
ҲûɶЧ

Фʱȴõ֯רҼ͹ҿίĿ϶
19993£ҿίΪФߡɹ֤顱ΪФоﵽ
ȡˮƽһƹӦáμݿƺ
ԺʿμӡаФоʦרҡпԺԺʿ÷档

ҵʿϷĩ֤ʵФõϣ÷Ժʿ
𵽾صáǰһֱϣФΪԺʿӰˡ

ݡй̨ܿǰԭȻѧίԱ
ѧҶרƽɽ족ȥġ

º1999ĳɹФҪã֮Ф
̻ùҿƼȽƽҽѧ

Фѧеġˡֻһһλҵרָ
˵ФļϿɷõĻôҿƼȽ
ĽûҽԺѧУ쵼֧֣ǲܵġ

ƽɽʵʩФΪФҵת۵㣬ڲУ
ƽɽΪꡱ

3. ʧ

Фһ˽ҽԺBeaumontҽԺչоȻҽԺ
˳ƣʧ

ڳɹܵٷ϶֮ФٽФõ˻
ĤĻϣԽ⡣人ҽԺС

2004꣬ԭҿίٴζФгɹ˴μר
ϴһǿ8רҵУֻһ˲Ժʿֵһǣר
רҵṹȴܵɣΪ˲Ժʿרңרҵ
ơң֪ʿ͸¶ϣΪרԱ÷
ԺʿҪΪФĳɹȡһλרҵļҪ
ʤ

ݡѧšμһλԺʿܲɷʱϣ˴μ
һЩء

1999ļμԵáء࣬˽
ԺʿŵġȡΪȽ֮⣬رᵽҪ
仡֧ױһ֧˶书ܣкܴա

γɹ֮õɽɾФҵڵĵλ3
·ڽϷĩ߲ɷʱФ˵ƣŵ


2006꣬Ф֣ݴѧоĿһȡԴ
ҽԺФܣӿҵȥţԴҽԺǧФ
2007ФβԺʿʱ֣ݴѧоΪФ
һ֤8£85ĻߴСָ
֤һ©Ϊ֤ʱ20072£ԴҽԺ
Ÿհ꣬ζŲ8µĲˡ

ФԴҽԺܿҲΪµʡڷӵ˵
£һڴƵĲˣФ˷ͥԺѾ
ݳƽ10·ݿͥղǵ˵ǻ3ԪꡰФ
鲢޸ƣеصĺ֢

2006꣬Фӭһ߷壬ʼϵٴ顣
ܣҲʦ÷Ľ飬ΪͿмֵԣйһ
ˣʮˡ

Фһ˽ҽԺBeaumontҽԺչоΪպ
ФҪʱȻҽԺٴҽԺڽ
һýɷʱȴĽʧ޷ش
ջĸ

BeaumontҽԺشѯҳܣ֮Կչо
ФйĳɹФҽѾ̸йҪҽԺ
ҽȻ ʵϣФйѧδõϣһ
ҽҲФïŵȼˡ

˽ҽԺʾзöҽԺ֧踶ѡ

4. Թ

жҵʿƣǷɣФ϶ѡԺʿ

˵2004ФꡱĻô̶һ֮
ۣӸ߷ϵ£һУԴڡѧ족ӡ

ƾٴͨҼФФпԺԺʿ־ڱ
á2003йԺԺʿʱѾڶ֡Ϊҽѧ̩
ĽӰˣФΪԺʿǰ϶¡

20059£йѧԺڹ2005Ժʿѡѡ
桷ФС914գһվ߷̸ʱ
䡰ФϷ仡δʹϣФˡԴޡһ֮󣬷
Ϸ£Ф

ФԻӦ10£ַȨΪɽӺһ
ϷԺһʽɴĻ

ФϷĩƣ䷢ѣΪԹ
ƣԼڡĽͳ¼УԡڡΪ
ӡ⻹ѧ־ٱӡϮ

Ϸĩ߳ƣʵһֱ2005˾ʱŴФ
֪ԭǡڡ

20067£人ԺоФʤߡǸ⳥
𺦸ο3Ԫ

һʤߺһ£Фɱطӵϳͬɽ
Ӹ浽Ժͬ10£Фٶ人ԷӺ
ϡ

200696գФֽ֪ѧҡѧ񾭿
㣬ķͥ

20073£Фԡ̰ԷߣԺδ


ˣФνӸϷԺֻеһʤߡ

ȻФԣϲδذܾ֣ѡԺʿж
ҵʿϷĩ߳ƣӶԴ𵽾ãɣ
Ф϶ѡԺʿ

5. 롰ӡ

ڹ״һϣԺʿһϣФȻûб֡ӡ
ƽ

Ф߷ӰһͥʱФʦ÷Ժʿ92䵽ͥ
ͦӡݵʱųı÷˵һֱ
йѧҡФԺʿǶֳƿ죬˵վ˵
ˣ

ʱӣ򡰴١θϷͥ⣬ҽת
ϵĴСʱѧҡФʱ֣˷ʿһ
ġ

ѳƣ֮վФһߣΪ޳Ф
ΪԷӡ

ͬˡʮֻԾФٸ淽ʱͦФıѧ
ϵԳ˵䱾֤ݳͥԽҷԣ
ð޹δ

ͦФͦΪأʼһսӵ֧ߵУһ
ΪYUSH˱ͦФΪС

֪ιʣһλںо֣ŮʿͦФΪǡYUSH
ŮʿյһʼҪ乫˿YUSH֮Ǹ
ܵͷ

֣Ůʿ֣ܵ˽ҲѾܴ˾ţ
֣Ůʿò˿ϷʾԼǡYUSH

ּս֮˫2008ͣڴڼ䣬Ф2007
ȲѡԺʿʧܸա

Ȼ20098£ΪԺԷӵġǿִСʹ˫ս
ٶ

ԭФ״淽ӵĵһ𰸼УȻ人طԺоФ
ʤߣȴٳδִУһֱо֮󣬷ͻȻ֣
˻Ԫ֪ϵ人ԺǿִС

Ϥʵıǣ人һλѧ׫дһƪڲΣ¶й
⣬ἰФ뷽Ӽ߰쵼ʾת
ʡ߼Ժʡ

֪߳ƣ˰人һλ˱뷨ٸλоҲ
һֱδִСȻ֮󣬴˰־ᣬԺԡΪɶԷ
ӡǿִС

һۣФٶü

20091219գФٱɶеФӦ
ѧݽⱻ֧߽ΪǶԷӵڣФ
Ŀǡ¡׬Ǯ𡢴ӡңںϷĩ
߲ɷʱФ䡰𡱵ĶǷӡ

Ф˵ġӡΪѽ⣬ڽϷĩ߲ɷʱ
ʹרŽͣǡƽġʮӣ꣬ûҲ
ܸҸԺʿҺܸˣǼٵģαôαأ

״һ±ԺʿϣФȻûб֡
ӡƽġ

Ф廪ݽ֮ıѧϵڲгƣФ
ĿǰûгΪйѧԺԺʿйѧԺйѧͬĳ衭

ΪǷӵġսѡշֵ𣬲Ŀ
Ф֮УᶨվФһߡФץ֮ڲ
д֧Фӵļ١Ф
ȥ㣡

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

Феƭ¹ҽ

ߣʸ

¹Tubingenѧ20059¿ʼʵʩʵʩ6˻ôѧ
200597ٴ鿪ʼŸУФɹ⣬
ƣ

13𣬰׹Ե
ѸٻָɹԼ80%Фĳɹʣȫͬ

ФѳơФйǳеĻ鱨
еġ92˻е88%110е87%ָ׹ܡһ
ԣƭһЩչٴ顣ֻѳЩٴΪٴӦã
Դڹƭڻߣͬʱֽ֮ڣչ⻼
Фʼٴ(XYS20100227)Դ
ȡ޶

Tubingenѧ13ߵФһԡʵ
ϣNIH1999Ф240ԪŦԼѧչƼ
˵飨5R01DK053063δʽһ
ݻժҪбԶѷФԼĽ磬ƽ
Ϊ200Ф15˲Ϊ31ŦԼѧ˺
ټ顣һ12߲μӵ飬BeaumontҽԺ
200612У3˻ߡ9ѡһ
ȫ򡱡

Tubingenѧ6ǣȫʧܣЩơФ
ϺSIU 2009ѧ͸¶ġ

6ȫʧûзTubingenѧKarl-Dietrich 
Sievertǩν31λѧͬԮФҽĹšл
ơBeaumontҽԺ֧ФġѾ֤ʵФ
ǰĽ⵽ġٴЧФǰĽȻͬǿ
ɣԭʲôΪʧܺФˣ ѡ
òԡ

μ

¹Tubingenѧ200597Ÿ
http://www.uni-protokolle.de/nachrichten/id/105332/
13 Patienten wurden bisher in den USA versorgt und wiesen eine 
deutlich schnellere Regeneration der Blasenfunktion von sechs Monaten 
auf, mit einer annahernd gleich bleibenden Erfolgswahrscheinlichkeit 
von 80 Prozent.

English translation:
So far, 13 patients had been treated in the U.S. and it showed a 
noticeably fast recovery of bladder function from six months, with an 
almost the same constant 80% success rate (as Dr. Xiao previously 
reported).

2. ФϺSIU 2009ݽ
http://xysblogs.org/wp-content/blogs/107/uploads//s80.jpg
http://webcasts.prous.com/netadmin/webcast_viewer/Preview.aspx?type=0&lid=10196&pv=2

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ѧļͦФ

ߣ

2010101գΪںſƽ̳ýһ˵ս
---Фı 2010-10-01 04:23:46Сʱ covet 
ȫǣ

ϻ裨Ф--ע˵׾ѧ羫Ӣй׻ý֮
սСС˵˻Ȩ2010-10-01 04:23:46

ǰѰѧο֣924ͬҲ
ýΪФױв绤ƣ

ʲôý»Ҫأܹôô̲
йýԽʵĨФԽ˻еè壬Ī
ЩݺФȲĨ·йý壬
2010-9-24 7:17:51
Ф߶ȿTortureĽФԱ
޶޶ΪûȡýչÿƶڱƹФ
ФǱİӣϣ
ôճ˵úܡ۶Ѳڱƹ2010-9-24 12:13:36

ФйˣĻ׿ڳϣʾ{ڡǻ˵
ʲôأ

ФڽѶƵͼ

óһѧͬԮФҽĹšݡ
û˵ˣ˵Ϊ̽2010-10-01 03:03:56ں
̳һǺǣƭӷӺͷ湷Ҫ˯þˡܣ

ܶѹѧͬԮФҽĹŷ͸ڵǺй
žǰФ 

˲ûģֻṩһӣѧѧġ
ųƴѧȴԷıһġġ
ٸ£δȥʣһֻҳĵλʾ6ƪ£
5ƪͦФģ¼ڴԱо

ѧ֤Ӳܱҵ
ѧͬԮФҽĹ
ƼӶФʼĩӵĿǡ
ФĹ¡
Ф :  
¼ӳȪ·ʵ֮Ұ916գ

ѧͬԮФҽĹšеһƪ뿴һ£
31˵˵

йӦΪФҽԲĹסĿѧɾͣ
ѵҽƹĳԺʿѧФҽв
Ϣе𾪡Щ˽Фҽˣ˰еš 
ФҽһͬĵʿĳʵͶԱѧĿԵĿѧ
ɾ͹ͬе𾴡ǿййȨԴФ
ڰڼ䱣ĻȨڴ¼УФ
Ŀѧ˵ҵĹס 

ȣ31ǷͿԴʿѧ硱ͬ͡СɣΪ
û˵ŵıй֮
֣ʱȥ31˶Фιס˽٣
ФѧǲǶԱѧ˿ԵĿѧɾͣȥۣ
ǾԷԼǶ°ƣѧ޹ءǡԮ
ФҪԮʲô

ں̳ϣϣ෢Щ˵ţΪʹٷ
ᴦܻͷšѵФͨ
˵ѾˣФסڿСҿһжʲ
ôı䣬

رзζǣ˹ǡū˵߹
Юأͷˣȴְ˽ѵйý壬
Ϊʲô3122ˡ

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ѧලΪ˶Թ
Ϯ˼

 µ˼
20100928սձ

۹עķϮǰơϮӵģǻпƼѧͬ
ҽѧԺЭҽԺФǰӶ٣δ
пԺԺʿĻѸƣȻ֪ʶӵ
¸ɥʧȱѧܻƵ⣬ʹġҵʿΪ
硢ܲŲ̨֮Чļܴʩ䡰˴١Ϊ
ල¼ûݵĿԡ

Ʋʳ

ҽʦʿʦ973ϯѧҡ˵Ф˶
ͷΣƱ׼߼֪ʶӣĴйȻ䱾˵Ըأ
󱳾¿ղФԺҲС
Դ¼֡

šƽ˹ȷƼ硢õߡ
ʽ֧վⱾһ£ƶȴȱݣڸ֪
ʶУй˹ɴѧĹơ

ФԺʿƺţҲһԺʿǹ
ĿѧѧƺţһȻѧ̼
Ժʿ̽츣᷽˲Сסɷϵǣ
ԺʿƺģиԴ⡢ѡȡƬ桢
ؿԺʿƺţФ֮ѡԺʿΪ˽Ҫ;
ΨһֶΡǣ·һϣ߳ŭˡѧ
ɣɴ˱ɸ˶Թ

µӢۡûСƺԮ

ʮǰĺӪƷӶƿ򱾡һȣ
һֱΪٶʿ˴αϮƺµ͵ΪӢۡ
绥רԣΪٶⱾӦ
еĽ󲿷ѧʿǡӡôױ
¼Ҳݡ

ϧڹڵѧȦп ࡱڽýɷʱ
˵ڲ˶ѧٺܿݣȡӹϡ̬ȣû˵
ˣ桱ΪǷӱ˵Գԭ򣬵Ҳ
ı

21ͽоԺԺܱͬ۵㡣Ф
ФϷ仡ǰڳʱǽƼ
ܲţǻпƴѧУ϶Դ˳Թ̬ȣûмʱ
ݷӵɽе飬Ȩѧ

1999˿վͨԼѵ£ҷ
ѧĸ󡣵ǡ¾սûܲšӰ
ӽҷߣȻԾѧȦδܵӦгͷմ
ȥĪ˵ѧ淶ؽߵĸ˰ȫ¶Աϡ

ѧͬ巢ܲſɳ

ǰλϽٱУĳѧߵѧΪ
ٱַȨΪɣԺߡСʱͥ󣬷
ʣǷѧ٣ĸȨŲö

ܱΪҲǵѧȦؽ⡣Ӷѧٵ
ִžȻֵ壬ӦΪΨһĲС͹˵ѧǳ
£һ·֡¼ǷЧҲ߼ʡ߼ǵĲ졣
šѧίԱԴʧͺװѧתΪһ
˶Թ߽¡ӡ

һȫѧϵͳУӺ˿վԼ˴ߣ
Ӧӵֻǡṩܣжѧ١ѧˣѧͬ
Դνѧͬ壬һָƼ硢ѧѧίԱ
ᣬؼҪһ͹ܼʱ޷ԤĶ
顣ֻȫĻƶǸˣѧܱܲÿɳ

ڸУԺŷѧ¼Դˣػ
ڡܱΪⲢ֮١Ϊÿһѧ˼١
ɵѧ˵ѧ޶ԣǶı˺
ȷѧʵֻѧ飬йĽ
ܽ๫֮ڣѧߡ

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

Фױ Ӧ衰ʺ

 
20100929-ƼƵ

28ͨ˵Ф뷽ѧжԹ
Ϊŭ֮ɵ¡

һͨФϮٶʿӺ͡ƾ־༭
ɡʲôɡڹҲ߲˲ŵĴ󱳾
£ѧѧĶԹױҼеļ
ȴܲǵľ˹ڷ֮顢
ϢԳƵƣšعЧŸ٣ҡײƭ

ⲢУšڴ˰ǰãӾͽҴһ
λع߾͵ĺ󾵡

μôҺ֡ռ价ĿѧҡάпԺ֮
6ºع汱ѧͿڱԺʿҹ丸Ŀϯ
ѧҡ915գҳƳԼ΢ƣǳ˿
΢ʶѡǼôҺϯѧң19ڹ
28Ҿ긻ǿʱعΪйһЩ顭

΢Ƴã׷Ҳɣάġô
ϯѧҡ⡣Ӿѯ֪άֻǼ
յؿѧĿļĿѧҡ֮һ滹СĿѧ
ҡΣǶһ޶ļôҺֵġϯѧҡ⣬
ӻʵԳӢдֵάӢдƷûз
ΨһƷԼڹ¼ļֱû

ʵάǾ޽еĸڴˣٱӰʵ¡
ļӰϴİ

2000꣬˿ѧҡšݴѧڡĴ죬Я
гɹ϶һ޶ֵ޷صЧ
ԼҲý׷Ϊʺ󡱡󾭷Ӳ֤
ɼһ˽ӪҽԺͨԱ䡰һ޶Ļ⣬3000
4000ԪͿ򵽣

2003꣬Ϻͨѧ΢ѧԺԺ½Գơнʮ
У뵼幫˾¼ɵ·ơ͹ֱӾ顱
Ѵ10ƬMOTO-freescale56800оƬͷ棬ѳƳ
֪ʶȨġоһš㶨˹ڼɵ·ҵ֪רңԴ
ΪӣʮҿĿƭȡ˸ߴԪĿл

ٽЩģǽ겻֮ƿѧšƿֻ
Ұѧ̫ƽѧĲʿȴԴҵĳɹԸơУ
Գǡѧѧʿձ˷ġOK
֡ͷרΪС

֮Ը˹Ȼ٣ƭһƬΪԺ蹵
ϢԳơͨһ͹ۡơ⣬Ҳѧ粻˵λ
޹ϵ

ФعġҵͲѿеĶߡԳ
ФϷ仡˹-񾭷仡ۣʱûеõ
ѧϿɣһ۵Ҳʵ飬û
оٴǣʦĳ֪ԺʿԴ˴Ӵ䡰
ŵڸԺʿټԼһЩأȻȺ
֯ФϷ仡ѧɹֱΪȡ͡
ƹӦã

⣬ڵһЩУԺȵλΪӿ⡢
ѧƽȳ룬˲ʱĶ󲻼𣬶Ժ
θΪӶװĴֻʵֻ
Ϊ鿪˷֮š

Ȼ񡰻ʺ󡱡򹤻ʵۡоӡĲȻ
ǽӰ֮Σ֮ȴСرȫزϧн
ģƸ뺣߲˲ŵĽ죬Ӧӡ

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ӽڹ˿Ժʿ

ߣ
20100928չձ

˽ڡФھͷǰ֪ʶ󣬹һ·š
¡֮ڣνڰϴɣרҵ֮
࣬ɢѧ򡣴żֵĽǶ˵ž
䶯ЧӦ

Фԡ()ıϮڱѡпԺԺʿ
˼ɣôʵճʶŬпԺԺʿ
ϵеĶе׷󣬶Ф־߱еְҵһϵСС
ɵģӦ˾ѧۡȻˡѧ٣
ýª:Фټ֡жµġ׷󡱣ͼ
ذسಲһδ뷽ӵȶԲãһٹʿ;(Ժʿ֮;)͡
·(˾)ϣգˡ

һ۶Ф׷ġԺʿݣֹ
档ϻ10Ԫף䱳߼:ǸԺʿĺԶֹһ
ʮ10Ԫ!ôӺʱԺʿͷþĹ?ֹ
ܶԺʿ˼˸ĸʴĿǰʲô̶?ԺʿѧƷѧص
ֹܵĴھжڹϵ?

Ժʿġ֮ʡǷǳҪġָ֮ѧ˸
ġ²˫ܰ췽ȷġ֮ƫǮ;
棬װļֵ۴;˿ǵǣЩԺʿ
ԽԽմ˽Ǯζ͹ˣФˣ
뷽跨ʶѧĹڣʧܻ֮߳
ŭȻǵɽֹѤۣɵõ֮˿?󣬼
ݷŲֹһФһСǵļóѣЩɽ
ߡԺʿɳľ?

ˣһ°кܳΪıѧͷζ
Ĺʱб¶ǽǮϼֵ۵ĺУֺе
ѾΪ役ǡФù˵ļ˰ٴ
鵽ֵб㸲ϢСԸҳǵľѣ
ѧ塣

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

Фİ֮͢м

ߣ

Ф΢̸ڰ͢ĽѧҸȤᵽڰ
̨͢ҶԴʵںЩʡ

ȣФǷڰ͢ҽִգûУڰ͢
ֱ޷¡Ҳһҽ
ܵйȥõйزŵ֤͸ҽӴ
İ͢͢ϻһԼģҺ
һ˸ңФԼҲ˵޷뻤ʿ˳
ͨųһ亹ʱҽͻʿϰܳ
͢ҽԺŻӲ
ΣФ̨Ҳ֪Фôģ
СɣФڴйɰ͢50ˣҪʱʿ
ϰ˫ҪͨФڴŻЩػй
ķϮĽչҪ̨ǲ˵Ļҽ
ĵı֤Ҳġ

ԣû֤ݵĻҶФڰ͢һ
ɡ

Фڱ󣬻Ϊ֮ϧرΪФҵн
ġФڵҵˮƽƺһ˿ѣеʴӵĸо

ҿʵֻһЩʶжϾˡФڵ
ƵôЧĻֻҪò˵ͳˡź£ҿ
򵥵£ФʼնûкüʮΪЧ׼
Ҳ֪ΪʲôҪó֤֤ФڵЧ
֤Ӧǡǡ෴㷽ӱо֤ΣФʼղó
ʵ֤ݵ£֤ҲӦתˡ

˶Фڵİ͡Һǲ⡣Ф˶ʵ
飬˵еͷοͷҽѧоԱҲ޵ĺܡõ
ɹƫ۵˵ӦCell, Nature, Scienceƫٴʵ
ĻӦNew England Journal of Medicine, LancetФڵJ. Urol.
־ȻҰҲ˵ФڵĿһĳɹ޵
ܡ

ĹؼФڲٴ֪ԭΪΡ
عƺܿʹģٴˡʵЩѲ˵С
оФһ㡣ͬʵ鶯ﻹܲû˵
֮ĳƺţǿˡлһ
ءűФ˶ʱҵԺĨȥձ
731ӵ󡣵ȻФǺ˵ģҲŴ̵Ʋ
ֻ̨ҪǮѡ

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

Фʵûа취

ߣzhaows

ФѾĴо仰ǿ۵ġԭ
Ǿʵûа취ʵûа취ǲǿΪʵ
ûа취֤ġФЧģʵûа취ӵɣʵ
ûа취кĻһȻҲʵûа취ƭһ
ƼߣڿѧԱ˵ѧСǾʵû
취ѧķߣӦа취֤ѧ۵ȷԡ
һ;ʵû취ˣֻ˵˵ǶԵģ֤ν
Ǽٵġѧ۲ǳ֣˭˵˭Ļ˭Ӯѧ
֤ݵģýලڻɵע⣺ɲǼ򵥵ķ񶨣
̵Ľ¶ФǱ̽¶ˡФҲ׿˵ˣʵû취
֤ġФЧеģ߻仰ʵû֤Ӵ
ļٴˡ

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ФġԴҽԺĹִգ˵ʲô

ߣCarnegie

ִգͬ˵Ŀҵʱ͹ʱкܴĲ˵
ҵʱ򣬲ûйעᣬעȻӪҵ

עţ 4101002940116 
ҵƣ ֣ԴҽԺ ˣ Ф 
סַ/Ӫҵַ ֣ж17 
ڣ 2006-12-31 ׼: 2008-04-29  
עʱ 100.0(Ԫ) ͣ Ԫ 
ӪΧ(Ӫ)  ڿơơơҽѧơҽԺӰơƾЧ֤˶޺ͷΧӪ  
ӪΧ(Ӫ)   
עϢ 
עأ ֣йרҵ־ עڣ 2008-04-29 
עԭ ԭ 

һңҲעˡ

ҵƣ ҽе人޹˾
ע  ţ ֵ003198  
Ӫ״̬ ע  
ס     人н˫֣ݰԢ㣴 
עʱ 20Ԫ  
ʵʱ 20Ԫ  
/* Ф  
׼ڣ 2008-05-08 

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ɽԺʿҽĿ

ߣ

ҰףڵһԹߡżϿһ
ɽԺʿҽĿı̲סһЩ뷢£

Ժʿ˼ڡҽδĹ֤ҽǿѧġҽ
δҽִҽѧؿչŵԤҽѧĴ
ŵĽʽΪִҽѧνҽ˼ҽӰ
졣ʵϣԤΪչܽĶԴһѵ̬
ȣڽͨ¹ʣսڵ𣬶ڼȵȣҪԤΪ
ڹŴǵȾͶԡԤΪѵʶֵԺ
Щܹ˾˵йŵҽѧνҽһſѧ

Ժʿõӣصĳɹǡǡַ֧ӹڡҩ
šؿǰΨһһַҩȫҽѧ
ϿɵҩΪǲִҩѧֲȡִҽѧ
֤ҩѾûѧϳɣ

Ժʿ˵ҩǧľ˲ٺöж;
ѭ֤ҽѧż顰ѭ֤ҽѧһʣõ½ͣѭ֤ҽ
ѧEvidence Based Medicineе֤Ҫָٴо֤ݣ
Ϳɿ̶ȿɷΪ弶ɿνͣһ
randomized controlled trialsRCTϵͳۡ
RCTƷ棬ʹϴ飨RCT
RCTϵͳ۽֤ĳƷЧԺͰȫɿݡ˵
ԺʿǸӵĹ۵˵һȥˣ

Ժʿ˵Ϊҽƺ͡δǿѧġ 
ѧScienceһйں͹㷺ãڽй½ĺ
ﾳѧġѾˡȷġͬʡȻһѧġ
ûʵ鷽ͱʵ֤ʵ۵ֻ֧֣صĹΪһ
ſѧҲͬΪƺδ ǿѧģȷģ
ҽ˳Ϊһſѧ磬˼ᳫ̬Ҫƽ
⣬Ҫһζ׷ʳӦƣҪڱʳѪӦעͨ
ҪͲҪгҪΥȻɡЩǿ
ѧģȷģȴ˵һǧǰ˼ҽ
һſѧҪ֪ѧĳ֣Ǽ顣

Ժʿ˵ҽֱӰ𣬶а桱
ҽѧвͬɣһʵбƷϢƷ
ҽͬҽ̸桱ΪûֶΡ

˵ҽܳڴڣȻĵڵδǺġ
ŻʮȥˣȥȻɼ̯ģȻ
Ѳģܿ˲ҷʴĸ̫Ͼ
ϵҮգһ·ݹȥһȺ˳ڴڵΨһΪ
ҪʱĽȻҲ˲Ϊǲ
Ͷҽɽҽ˵⣩ҽͬû̵ĺ
żлܵĿĵأҽ̵ͬĺżҲﲻĿĵأ
Ըѡ̵ĺһλִҽѧƳߣڱ֮
ʱҲסȰ뿪ЭҽԺȥһҽ޹
صЭ͡

зζǣʮᳫҽѧҽΪҽ
жôȽΪҽڡ֮Ҳ֮УҪȥѧ
ҽʵΪѣֻкҽоҽȽϿУȡ侫
ȥɡϼʮҽѧҽû˵չҽһ
ѧ˰ҽšҽҩΪҽѾĿ
ǰҽھĹ̡һҽԺҽ豸ҽ
ԲûͿѪBCTҽټϼ
顱֮ҽ󣬴һӿҩɷֵгҩ¡

˵ʵڵģ߻ͦϲоҽģϵġҽѧۡҲż
ϻ𡱻ȿˮΪˡĿݾջӲ裬ȵȡ
ǶĻйأҪ˵Ҳȥ
ҽԺġţǹŴġйĻƷֻҪϵĿѧ
֤ʵЧģᱻִҽѧ֮С
ҽѧµıŲǷḻĻ⣬ֵо
ʵ̫࣬ҩоӦǻִҽѧģǻڻƵ
ھҪԵġоҽӦǽִҽѧҩѧѵĲʿо
ҽѧstudyҽҽоԺΪҽѧԺʮЦϡ

ˣ±ԭǡɽѷӡ
ղٿĿѾΪɽƷҽѧ˵̫ԡ
ʵڿɾ塣ʵԺʿеһЩ۵ʵ뷽
࣬ͨȫģԺʿҲû˵һ䡰ҽһſѧ߸о
Ӹҽҩ֣Ժʿҽҩķ㼰
ǲȫڼߵʡԣҪٹϼͷϵƪ
µıˡɽͦӡ߶ʱļ߻༭е
⣬һҲ֡

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ʷ

ߣҽֳ

ѵһƪϲС˿Цõģ򷽡й֪Ⱦ
¼ıΪϱشƼԹЧ۲족ӢıΪ
Edaravone United Edaravone Injection the treatment of acute cerebral 
infarctionΪɶۯҽԺǮˣ200926ڵ
ҽơϡѪܵҽԱĿܲʲôÿ
˿ӢĿϻᷢˣ ش桱ҩѽ
ش桱Ʒѡ˵ţţƿڿʵЧ۲족
ҵֻܲһ뷨ðźܴķе
йķƶĬս-------ҾдƪЦĿܲ
ͨ༭ͨ˲շɹˡ 

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

Ϊι

ߣdivingbird

ǰôһ¡ݷԭԴҽѧ
ˣ֪ʲôԡADAMѪ֡Ȼÿ춼
̳ҡ
http://www.xys.org/xys/netters/others/net/kaihou.txt)أλ
ߺ󱻰˸ʾ¡

ȥȻּ˾йũҵѧѧ201001ڡ
ΪֲƵƼоӦýչкͺĩ
http://www.cnki.com.cn/Article/CJFDTotal-NYDX201001020.htm)

ǺҲȥԭ˿2002Ͷλľ֪
й
http://www.xys.org/xys/ebooks/others/science/dajia2/shengpin.txt

ݰٶȰٿƽ
http://baike.baidu.com/view/2319078.html?fromTaglist조1964
ѧҵ䵽½ҵѧԺȡ1994½ũҵѧƱҵ
ĺ30ҡǲǿȥеѪԵϵأӵЪ˹
˵Զ׼ģۡĪСһҲΪɡ

ˡ¾ʹ˹ҹֶ¶ôһ㣬Ǻǡ

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ƭڹĴĦֿ캣пʵ

ߣoztiger

·͸磺Wind could have parted Red Sea for Moses?
http://www.reuters.com/article/idUSTRE68K3PS20100921
йѧҼģ ֺ캣ֿ
http://www.chinanews.com.cn/gj/2010/09-25/2552395.shtml

˵ѧǰüģóۣʥصĺ
ˮֿȷǿ·ǵо͡ǡ
едʮǺϡ

ǣ
1ģʱʹõǿʱϰٹ12̨磬ͱˣ
ʲô

2ģʹõĵص㲻ʥصĺ캣Ƶ޺ӿڣ
ʮ׵ˮ׶࣬ˮˮȥģ⡯
Ħ캣塣

ʵʵܼ򵥣оCarl DrewsǸϵ˵
дļ֤http://www.theistic-evolution.com/mystory.htmlֻ
ԿеĻΪԼĿ绤ѡ

˽ͽͼƴաֺ֤Լһӣ
ΪͽȻ֪Ħ캣ŵˮǽ
εĿյȫͬǶѧȻ֪ӵˮ캣ˮ
ȫͬģΪѡ

νоᱻκѧʿΪѧȻⲻͽ
ǽֵ

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

335PH4CVרļժ룩

ũѧ  2010-9-27

United States Patent 6,897,363
ר6,897,363
Inbred maize line PH4CV
ԽϵPH4CV
Abstract
ժҪ
An inbred maize line, designated PH4CV, the plants and seeds of inbred 
maize line PH4CV, methods for producing a maize plant, either inbred 
or hybrid, produced by crossing the inbred maize line PH4CV with 
another maize plant, and hybrid maize seeds and plants produced by 
crossing the inbred line PH4CV with another maize line or plant and to 
methods for producing a maize plant containing in its genetic material 
one or more transgenes and to the transgenic maize plants produced by 
that method. This invention also relates to inbred maize lines derived 
from inbred maize line PH4CV, to methods for producing other inbred 
maize lines derived from inbred maize line PH4CV and to the inbred 
maize lines derived by the use of those methods.
һΪPH4CVԽϵԽϵPH4CVֲӡԽϵ
PH4CVֲӽֲ꣨Խϵӽ֣ķ
ԽϵPH4CVƷϵֲӽӽӺֲꡢ
ŴкһתֲķԼַ
תֲꡣ漰ԽϵPH4CVԽϵ
ԽϵPH4CVԽϵķԼЩ
Խϵ
Inventors: Barker; Thomas Charles (York, NE)
ˣBarker; Thomas Charles (York, NE)
Assignee: Pioneer Hi-Bred International, Inc. (Johnston, IA)
רȨˣPioneer Hi-Bred International, Inc. (Johnston, IA)
Appl. No.: 10/271,942
ţ10/271,942
Filed: October 15, 2002
ڣ20021015
Current U.S. Class: 800/320.1; 435/412; 800/275; 800/278; 800/279; 
800/281; 800/298; 800/300.1; 800/301; 800/302; 800/303
800/320.1; 435/412; 800/275; 800/278; 800/279; 800/281; 
800/298; 800/300.1; 800/301; 800/302; 800/303
Current International Class: A01H 5/10 (20060101); A01H 001/00; A01H 
004/00; A01H 005/00; A01H 005/10; C12N 015/82
йA01H 5/10 (20060101); A01H 001/00; A01H 004/00; A01H 
005/00; A01H 005/10; C12N 015/82
Field of Search: 800/320.1,266,275,278,279,284,298,300.1,301,302,303 
435/412
800/320.1,266,275,278,279,284,298,300.1,301,302,303 435/412

Claims
ȨҪ
What is claimed is:
ȨҪǣ
1. A seed of maize inbred line designated PH4CV, representative seed 
of said line having been deposited under ATCC Accession No. PTA-4673. 
ΪPH4CVԽϵӣָԽϵı׼ѱ
걾ղģATCCǼǺΪNo. PTA-4673
2. A maize plant, or a part thereof, produced by growing the seed of 
claim 1. 
ֲȨҪ1ֲ١
3. The maize plant of claim 2, wherein said plant has been detasseled. 
ѱȥ۵ȨҪ2ֲꡣ
4. A tissue culture of regenerable cells produced from the plant of 
claim 2. 
ȨҪ2ֲϸ֯
5. A protoplast produced from the tissue culture of claim 4. 
ȨҪ4֯ԭ塣
6. The tissue culture of claim 4, wherein cells of the tissue culture 
are produced from a tissue selected from the group consisting of leaf, 
pollen, embryo, root, root tip, anther, silk, flower, kernel, ear, cob, 
husk and stalk. 
ȨҪ4֯֯ϸ֯ҶƬۡ
̥ϵ⡢ҩ˿롢ᡢҶѡ
7. A maize plant regenerated from the tissue culture of claim 4, said 
plant having all the morphological and physiological characteristics 
of inbred line PH4CV, representative seed of said inbred line having 
been deposited under ATCC Accession No. PTA-4673. 
ȨҪ4ֲֲ֯꣬ԽϵPH4CV̬
״ָԽϵı׼ѱ걾ղģATCC
ǺΪNo. PTA-4673
8. A method for producing an F1 hybrid maize seed, comprising crossing 
the plant of claim 2 with a different maize plant and harvesting the 
resultant F1 hybrid maze seed. 
F1ӽӵķȨҪ2ֲ벻ֲͬӽ
ջF1ӽӡ
9. A method of producing a male sterile maize plant comprising 
transforming the maize plant of claim 2 with a nucleic acid molecule 
that confers male sterility.
ԲֲķÿɵԲĺתȨҪ2
ֲꡣ
10. A male sterile maize plant produced by the method of claim 9. 
ȨҪ9ķԲֲꡣ
11. A method of producing an herbicide resistant maize plant 
comprising transforming the maize plant of claim 2 with a transgene 
that confers herbicide resistance. 
ݼֲķÿɵ³ݼԵתתȨҪ2
ֲꡣ
12. An herbicide resistant maize plant produced by the method of claim 
11. 
ȨҪ11ķĿݼֲꡣ
13. The maize plant of claim 12, wherein the transgene confers 
resistance to an herbicide selected from the group consisting of 
imidazolinone, sulfonylurea, glyphosate, glufosinate, 
L-phosphinothricin, triazine and benzonitrile. 
ȨҪ12ֲ꣬бתƵĻͪࡢࡢݸ좡
좡L-ݰ좡຺ͱȳݼпԡ
14. A method of producing an insect resistant maize plant comprising 
transforming the maize plant of claim 2 with a transgene that confers 
insect resistance. 
ֲķÿɵ¿ԵתתȨҪ2ֲ
ꡣ
15. An insect resistant maize plant produced by the method of claim 14. 
ȨҪ14ķĿֲꡣ
16. The maize plant of claim 15, wherein the transgene encodes a 
Bacillus thuringiensis endotoxin. 
ȨҪ15ֲ꣬еתԱBtڶء
17. A method of producing a disease resistant maize plant comprising 
transforming the maize plant of claim 2 with a transgene that confers 
disease resistance. 
ֲķÿɵ¿ԵתתȨҪ2ֲ
ꡣ
18. A disease resistant maize plant produced by the method of claim 17. 
ȨҪ17ķĿֲꡣ
19. A method of producing a maize plant with decreased phytate content 
comprising transforming the maize plant of claim 2 with a transgene 
encoding phytase. 
ֲøֲķñֲøתתȨҪ2
ֲꡣ
20. A maize plant with decreased phytate content produced by the 
method of claim 19. 
ȨҪ19ķĵֲøֲꡣ
21. A method of producing a maize plant with modified fatty acid 
metabolism or modified carbohydrate metabolism comprising transforming 
the maize plant of claim 2 with a transgene encoding a protein 
selected from the group consisting of fructosyltransferase, 
levansucrase, alpha-amylase, invertase and starch branching enzyme or 
encoding an antisense of stearyl-ACP desaturase. 
ε֬л̼ˮлֲķñתø
ø-øתø͵۷֧ø֮һ뷴stearyl-ACP 
desaturaseĵʵתתȨҪ2ֲꡣ
22. A maize plant, with modified fatty acid metabolism or modified 
carbohydrate metabolism, produced by the method of claim 21. 
ȨҪ22ķľε֬лε̼ˮл
ֲꡣ
23. The maize plant of 22 wherein the transgene confers a trait 
selected from the group consisting of waxy starch and increased 
amylose starch. 
ȨҪ22ֲ꣬תʵۻֱۡ
24. A maize plant, or part thereof, having all the physiological and 
morphological characteristics of the inbred line PH4CV, representative 
seed of said inbred line having been deposited under ATCC Accession No. 
PTA-4673. 
ԽϵPH4CV̬״ֲ٣ָԽϵı
׼ѱ걾ղģATCCǼǺΪNo. PTA-4673
25. A method of introducing a desired trait into maize inbred line 
PH4CV comprising: (a) crossing PH4CV plants grown from PH4CV seed, 
representative seed of which has been deposited under ATCC Accession No. 
PTA-4673, with plants of another maize line that comprise a desired 
trait to produce F1 progeny plants, wherein the desired trait is 
selected from the group consisting of male sterility, herbicide 
resistance, insect resistance, disease resistance and waxy starch; (b) 
selecting F1 progeny plants that have the desired trait to produce 
selected F1 progeny plants; (c) crossing the selected progeny plants 
with the PH4CV plants to produce backcross progeny plants; (d) 
selecting for backcross progeny plants that have the desired trait and 
physiological and morphological characteristics of maize inbred line 
PH4CV listed in Table 1 to produce selected backcross progeny plants; 
and (e) repeating steps (c) and (d) three or more times in succession 
to produce selected fourth or higher backcross progeny plants that 
comprise the desired trait and all of the physiological and 
morphological characteristics of maize inbred line PH4CV listed in 
Table 1 as determined at the 5% significance level when grown in the 
same environmental conditions. 
״ԽϵPH4CVķ1PH4CVӣ׼
ѱ걾ղģATCCǼǺΪNo. PTA-4673ɵ
PH4CVֲ꣬ĳ״Բݼ桢
ʵۣƷϵֲӽԲF1ֲꣻ2ѡ״
F1ֲԵõѡF1ֲꣻ3õѡF1ֲPH4CVֲؽԵõ
ؽֲꣻ4ѡ״ͱ1еԽϵPH4CV
̬״ĻؽԵõѡؽֲꣻ5ظ3ͣ43
λϣԵõѡ4ľ״ͱ1еԽϵ
PH4CVȫ̬״ֲͬ5%ˮƽ
ؽֲꡣ
26. A plant produced by the method of claim 25, wherein the plant has 
the desired trait and all of the physiological and morphological 
characteristics of maize inbred line PH4CV listed in Table 1 as 
determined at the 5% significance level when grown in the same 
environmental conditions. 
ȨҪ25ķֲֲ꣬״ͱ1еԽϵ
PH4CVȫ̬״ֲͬ5%ˮƽ
27. The plant of claim 26 wherein the desired trait is herbicide 
resistance and the resistance is conferred to an herbicide selected 
from the group consisting of imidazolinone, sulfonylurea, glyphosate, 
glufosinate, L-phosphinothricin, triazine and benzonitrile. 
ȨҪ26ֲ꣬״ǳݼԣĳݼͪࡢ
ࡢݸ좡좡L-ݰ좡຺ͱ֮һ
28. The plant of claim 26 wherein the desired trait is insect 
resistance and the insect resistance is conferred by a transgene 
encoding a Bacillus thuringiensis endotoxin. 
ȨҪ26ֲ꣬״ǿԣ⿹ָɱBtڶصת
Ŀԡ
29. The plant of claim 26 wherein the desired trait is male sterility 
and the trait is conferred by a cytoplasmic nucleic acid molecule that 
confers male sterility.
ȨҪ26ֲ꣬״Բԣ״ɿɵԲԵ
ϸʺ
30. A method of modifying fatty acid metabolism, phytic acid 
metabolism or carbohydrate in maize inbred line PH4CV comprising: (a) 
crossing PH4CV plants grown from PH4CV seed, representative seed of 
which has been deposited under ATCC Accession No. PTA-4673, with 
plants of another maize line that comprise a nucleic acid molecule 
encoding an enzyme selected from the group consisting of phytase, 
fructosyltransferase, levansucrase, alpha-amylase, invertase and 
starch branching enzyme or encoding an antisense of stearyl-ACP 
desaturase; (b) selecting F1 progeny plants that have said nucleic 
acid molecule to produce selected F1 progeny plants; (c) crossing the 
selected progeny plants with the PH4CV plants to produce backcross 
progeny plants; (d) selecting for backcross progeny plants that have 
said nucleic acid molecule and physiological and morphological 
characteristics of maize inbred line PH4CV listed in Table 1 to 
produce selected backcross progeny plants; and (e) repeating steps (c) 
and (d) three or more times in succession to produce selected fourth 
or higher backcross progeny plants that comprise said nucleic acid 
molecule and have all of the physiological and morphological 
characteristics of maize inbred line PH4CV listed in Table 1 as 
determined at the 5% significance level when grown in the same 
environmental conditions. 
ԽϵPH4CV֬лֲл̼ˮлķ
1PH4CVӣ׼ѱ걾ղģATCC
ǼǺΪNo. PTA-4673ɵPH4CVֲ꣬бøֲø
תøø-øתø͵۷֧ø뷴
stearyl-ACP desaturase֮һĺӵƷϵֲӽ2
ѡӵF1ֲԵõѡF1ֲꣻ3õѡֲ
PH4CVֲؽԵõؽֲꣻ4ѡӺͱ1
еԽϵPH4CV̬״ĻؽԵõѡؽֲꣻ
5ظ3ͣ43λϣԵõѡ4ľ
Ӻͱ1еԽϵPH4CVȫ̬״ֲͬ
5%ˮƽĻؽֲꡣ
31. A plant, with modified fatty acid metabolism, modified phytic acid 
metabolism, or modified carbohydrate metabolism, produced by the 
method of claim 30, wherein the plant comprises the nucleic acid 
molecule and has all of the physiological and morphological 
characteristics of maize inbred line PH4CV listed in Table 1 as 
determined at the 5% significance level when grown in the same 
environmental conditions.
ȨҪ30ķġε֬лεֲл
̼ˮлֲֲ꣬кӺͱ1еԽϵPH4CV
ȫ̬״ֲͬ5%ˮƽ


עѧӢĺѧֲŴѧת򣡼ȲũѧӢ
죬ôܶרף335PH4CVר׷ǳϽ
ֻҪ涮Ӣģ²ũѧҲΪǡת򣨻ת
֣Ʒֻ֡רʽҪ˻֯PH4CVΪϽ
ת򡣣2010-9-29

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ĶзĻָЧ

¾ 
ҽѧԺ

·͸罡Ƶ ݶ10ʹüĻαΪյ
ĵĽĲܰз߼ٻָ

ǴϸαķûʾĶк
ָܻлáϺWonkwangѧJae Cheol Kongʿȷڼ
ôҽѧЭڿCMAJϵܽ

һЩо֣ȣĶԻ档Ǵͳҽ
һְοշʽѨλ̡ǳƤͲ
Ƥ

磬о֣ĶЧһоʾͳҽ
ܾĳɹ档

ȻѾһЩĶз翵ҽѧоע
⵽ܶооԣ粻޹ҷо档

Ϊ˽⣬Kongȼ25ݿ12Ĵͳҽѧڿ
664ݹоУ10оǵı׼711ߡ

ǱȽٵ̼飬˸α
οյġͬķĲܸƻ߽ճ
Ҳûбֳ񾭹ܵĲָꡣȻоҲ
ĵ洦оֲڵıصƫṩɿ֤ݣ
Kongд 

оԱϣĿܲİοʵҲܲЧ
ӦԽͼ֮ûв𡣱о
ȱ㡱ȱݵϲǲ˵

뱾оͬʱУɶҽԺHongmei WuʿΪڱ
оģСҼʵϿҲһЧʵó
翵ЧĽΪʱ硣

Ҫϸ񡢴ģĵһĶз翵
ЧWu˵

Acupuncture not helpful for stroke recovery
(Reuters Health) - Acupuncture does not help speed recovery after 
stroke, according to an analysis of 10 trials using fake or "sham" 
acupuncture as a control.
"Our meta-analysis of data from rigorous randomized 
sham-controlled trials did not show a positive effect of acupuncture 
as a treatment for functional recovery after stroke," Dr. Jae Cheol 
Kong of Wonkwang University in Iksan, South Korea, and colleagues 
conclude in the Canadian Medical Association Journal (CMAJ).
Some recent studies have found no benefit for acupuncture when it 
is compared to sham acupuncture, a placebo version of the traditional 
Chinese medicine technique that can involve needling non-acupuncture 
points, penetrating the skin shallowly, or not penetrating the skin at 
all.
For example, recent studies found acupuncture was not effective 
for inducing labor, while another showed no benefit of the traditional 
Chinese technique for improving the success of in vitro fertilization 
(IVF).
While several reviews of the medical literature on acupuncture for 
stroke recovery have been published, the authors of the current study 
note, many have had limitations, for example failing to include 
studies published in Asian countries.
To address this issue, Kong and colleagues searched 25 databases 
and 12 Korean traditional medicine journals. Among 664 studies on the 
topic, the researchers found 10 that met their criteria, including 711 
patients in all.
Two of the trials compared real acupuncture to sham 
electrostimulation, while the other eight used sham acupuncture as a 
placebo. Several different analyses of the trials found acupuncture 
did not improve patients' ability to perform activities of daily living, 
nor did it show improvement in measurements of neurological function. 
While two studies did find a benefit for acupuncture, "poor reporting 
and high risks of bias rendered both studies less than reliable," Kong 
and colleagues write.
The researchers acknowledge that sham acupuncture may not be a 
true placebo, and could actually be producing physiological effects, 
which could explain the lack of difference between the fake and real 
acupuncture groups. Other "drawbacks" to their findings include the 
lack of data and the often-poor quality of that data, they add.
In an editorial accompanying the study, Dr. Hongmei Wu of West 
China Hospital in Chengdu argues that given the small size of the 
studies, as well as the fact that sham acupuncture may actually have 
some effect, "it is premature to refute the effects of acupuncture in 
treatment of stroke rehabilitation."
"Rigorously designed, large, multicentre randomized trials are 
needed to assess the effects of acupuncture on stroke rehabilitation 
further," Wu concludes. 

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ҽſҩ һ˴25Ԫ

   ʯ
Դ¾ 20100929

ע

а׵Ĳˣҽάѿθõ9ֲ
ڿ24.8ԪĴ

ԶĲˣάѿܲȫ19ֲ
ʱ䣬14Ԫ

Ľһģλ˶ûκá

λơʮм֢õĺ
ʯҽкζҽοҩ

գ߶Դ˽е顣

ҽάѸ֣Сӡ󣬴ӡҽƭӡǰ󲻹3¡

ҽҽʮأҽ߳ҩ""Ƽ£
3£а׵֣СĽҵʯר֢
άѡ

άѿȫҡġƿڰ֣Сﻼ9֣֡С˵
13ΣжϻӹܰͰά70ڿ24.8Ԫ
ɲδת

531գ֣СﵽݶҽԺ飬ڲްϸ

ϡƿڰһѲ

45֣Сڽ321Ľҵάѵġ

֣С䣬2005꣬Ƶ򼱣ڶҽԺ飬
ס롢ҩЧԡ

2008ףأת人ЭҽԺǰס

ҽ˵ԲβϸҲв֣С
Чڼͬ£Ӷϼҵʯλڻʯ̲԰

ʯֵϢʾע2005111գΪ
Ӫԡ˺Ҫ˾Ϊάѡ

֣С֣֣άѷֱ

ʲô֣ʡ

ûϸֻ˵ء

֣СſֵĻڣȻϸꡣĩˣͳһұ
հҽԺ֢רĲһ¹9ֲθáܰסʳ
衢֢֢ӹܲȫסȾ

֣С˵ԼʱһЩܲκã

õĴǣȫĲκá

֣Сάѿǰ죬־˵ҲõˡĲ
κáĴ𸴡

ӴСС˵ǰӵ人ЭҽԺ
飬ϽԶҽ˵βˡ

Ҳ˵Ľ£318գҵάѡ

־˵άѿиص㣬ǰȽ£ǲͬ
ƣǧٹֵĲ֣֮ͳͳκá

һθ־ﲡάѾǴһ¿ʼġһŮ˻
ڻʯôζβãת人ȥƣûЧҵ
ң֢κˡ

С˵άѿʱøеֻۿ־ƿ
ʱһӡ

7""άѰ־ƿͳһñʹ
19ּ˥Ѫ֢ܲ񾭼ή֧סܲȫȡ

һôࡰСַɵۡ

6ҩ3ࡰǰۡ

άѿҩҸסˡ

һοҩ15260.7Ԫ˵ǰۡ

˰˾Ԫҩ󣬲鲻תСַ̲סˣһʺ
ʱκá

άѸǴ˸ȷ͸һҪʣˣ
ת硣

514գ־鿴12Σ14ԪǷά3000Ԫ

֣СﻨҩϵǮࡣ

˵άѵһһ6ҩ˵ϣ
ۡ

ۣ֣Сһ34500Ԫʲôҩôάѽͣ
Щǲҩܵߵţơ㣬ҩġ

֣Сԥ˰죬ҵĲ˺ܶ꣬ĺܽǣ˵κã
һԡ3ҩѴǷ4500Ԫֽװҩĵ
ؼˡ

ǰάѸ֣СҩӣҲ
ģΪŶ

6֣Сڶεҩ2.4Ԫ4000Ԫֽ𣬴2
ԪǷΣҩ3Ԫ70ڣ֣СȺ13οҩ248660Ԫ
֧151660Ԫֽ⣬97000ԪǷ

Ƴ̺֣СǵãάѰƿ9ӡѾ
5⣬ά֧֣СӹϢ֣С
ļˡ

֣С˵άѰѡ顱˵ҵӹѾת
ܰͰ

֣С˵ҩ£״δ⡣Ҳǹͣҩõ
ͣҩǰͰ׳ˡĴ𸴺ֻü

531գһֱŻ˵֣С˶жҽԺҺϸ
TCT浥ʵҼδϸƤڲϸ

֣Сˡ

ҽҽҽѧɲ

֣ͬǶˣǰʶɺϵǣƼάѿ
мˣͬΪһũ

ڶݳũźΪ֣Сɷ÷źҽʶ

90ʪؽףβũұ
Զ˽ܣҵڱհҽԺҽάѣ˺
˱άҽ߳

ʾ193715գάڴұбϪ塣

918գάܷʱ䣬ֻ4µ飬12֮ǰŸĸ
ũ12꣬һϼҽҽϪ壬ʷ꣬ؼ
Сס

ά˵ڴҽϣѧ˱400ҩҽǰ
һҽ顣Գƿѧɲš

ά3ɳú󹤣ֱ1977ꡣ䣬
ϱҽ뿪ɳúǰ⡱

80άѿʼڼ681991ʱԳѪ
ҿǸʱ쿴˾ųӡ

1997꣬ʯ¾ұʯؼУ¾ָάѰ
ҽҽʦʸ֤

һάǣͷڵؽұհҽԺԺ2001꣬
ʡ·104Ź棬άִҵҽҽʦʸ϶

հҽԺϵġҽԺ顱ᵽ롢ʡλ쵼
Ժô30Һ͵ǧʻԺ
סԺʮм֢ߣ఩֢ߣ
ܺʿĺ

2002һͼ鹫˾ġά֢һУ27
֢23֢ÿ涼оٲֻһˣЩ
հҽԺΣ

άѽܣи˽ˮƽѪ人
κˡ

921գշתҵˮƽļˣ֤ʵˮƽȷܹά
ƣѿ꣬ʵάѵг룬ˮƽڽά
ǰ人ҽԺεú˰˳ɡ

հҽԺϵļʾ贲λ60ţ˴Σҽ
Ա32ҽ֢רơרƵ10ңӵж̨߾
豸ֵܼԼ300Ԫ

917գںʡϣұհҽԺĵ
ϢΪʵдλ20šְ21ˣԪ豸50-100Ԫ豸
100Ԫ豸Ϊ0

918գҵλڱϪհҽԺҽԺ3¥δҽ
ҲδסԺˡ˵ҽԺѺܳһʱδβˣҩˡ

šȫһῴƿ

֣С־ʾ֮άѣƵġ߳ҽ
ά϶صġ⻷

ʯϢʾάκʡھŽЭίԱʯЭί
ԱұСʯйּලԱйоԱٻҡʡи
ࡰȽˡٳƺš

άҽҵԼ֢
ڻʯҽγɽϴ󷴲

ڻʯһܵĲɷʱڣ20⳵˾δ˵
άѡ֡ʯҽƣҽ翪ҵֻᣬδάѵ
Ӱ

ʯһλԸ͸¶ҽƣǰʯһЭίԱ˵θ
βҵάѡƣ˼ζҩȴԳθͣ
¡ߺҽԺ飬θáҽԺƣſ

άƿڰϷʽûӡ̡ܼ߲ɷʱԳƣ
ȫйһ˻ῴƿ

ƿڰĿѧԣְйҽѧѧԺҽѧϢо
￱ƣδš

ܣҽ򽲣ͨԶжϣ
ϲ顣ƻڴûжֻѨλһǳҪѨλ
Ϲȡڼȡ

ҽǶȽ¼˵ĺйϵ

⣬ӽѧǶȿڴƤ֯ͼֻ΢СëϸѪܣû
дĶ;

ΪǴҽҽǶȣδ˵

Э̡ΪǮ

֣С־˹ĵǣάЩҩô
ô󣬵ĻǼٵġ

λʯҽһάѿ֣СĴŴܹ23
ζҩҩ3603.2Ԫ/Ԫ硢ܵغ컨ѩţ5ζҩ
󲿷ΪͨҩġЩҩûرԣȡⶾѪ
ΪҩأҩԺܴθܲˣθҲԻ

ŴУԪ磨㣩һ6ˡұҽԺһλҵ
48ҽƣô㣬һҩ̵ĴһҽԺҩ
ûôȫбҪЩʵԡ

˽⣬ҽĿ¼ҩļ۸񣬲ָ۷룬ϡȱ
ҩģ۸оС

߷ûʯҩ㷢֣άУţơܵ
㡢ȶζҩģгۡڻʯұ
ҽԺԼߵѯҩԱҲֻһҡͷ

918磬άѽܱ߲ɷʱҩԴʵԵɣ
δӦ

֣С˵98գýع⡰ҩ죬ʯҩಿǰ
ȡ顣

919գʯҩĴǣҩΪţơ㡢ܵ
ζҩУΪмҩֻţƿԳ浥ҩƷ
⡱ζܵ㣬ؼҩ߱浥ʸ

߷壬ʯҩಿδҩĽ

άѵĶ˵ʯҩಿȺ3ǰ飬
ǣҩĵĴ滷Уҩĵʹãѯߵ
ṩҩĵĽƱ

921գ֣ССֽеһЭ̣Ӧ辭÷Ĳ


˵ǮҪǻһ˵ά""С˵

ǸǮĿģǳ⣬ǿǵѸߣӰ
߽͡

Сдһţ㡣

磬֣˵ûõǮ

ԭҸˡһ֣СҪɾǰ
ϷͶӣɾ꣬Ǯ

˵˰73άͻ˱ϼң
ҽˡ

Ի

άѣ߻24Ԫ

¾˿ʱѧ

άѣҿĳܼ򵥣Ǹ˰ƿûаյģ
ȥҽԺ飬ϵģϵƣϵģ顣

¾ƿϳжּ

άѣ˵ƿ9999ӡһٲͻӣ
ƿϾͻзӦ֢Ѫܣ֢ëϸѪܡ

¾λʯҽҵʮ꣬û˵ƿ
ϲ顣

άѣκνڶȫйһ˻ῴƿú
ʱλиձľͳҽձͶʱû뿪йƿڰļ
ҵģѧ4ꡣϧˡ

ÿ˶һ֮ҿķ

¾ǿƿϳ֣С9ֲ־19ֲ

άѣǵģƿ

¾Ϊʲô֣ҪôǮ

άѣҩôѽֲթƭ־鲻ǰ֢Σ
ر5ΡңҲŴӦβһ㿴ǶԷ
εģûд

¾Ͽһ24Ԫһ14Ԫ˾ù

άѣûƭһǮԸģҩҲԸġ
ʱùԲûЧԲûбǡ

¾ҩأ

άѣҩֵҵҩЩȻƽ𻹹Щ˵ݣ
22ҵĳֻҪ11

¾Щҩأ

άѣ˽¡˵ҵҩ󣬿Եҩȥ
ҩ󣬻ҩҩ

¾ʯұҽԺҩ˵û㴦ᵽļζҩ
ܵ

άѣԡҲһ洫ط

(XYS20101001)

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

һΪ˰޷˿վĹ˽˿վĶ̬ؿ
˿ʼбxys@yahoogroups.com

ʼбÿ췢һ˿վ¸µϣÿµ׷һÿ
Ŀ¼ʼбĶμ롰˿֮ѡ
ʼбxys_friends@yahoogroups.com

ù䶩ġù䣬ܿ޷յ
Ƽ䣺yahoo.com, hotmail.com, gmail.com

ġ˿ʼбĵ䷢һհż

xys-subscribe@yahoogroups.com 

塢ͣ˿ʼбͣ䷢һհż

xys-unsubscribe@yahoogroups.com 

Ͷxinyusi@yahoo.comôıļͶ塣

˿(www.xys.org)(xys4.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)
